Gamlen Tableting partners with HDK Solutions
Companies are working together to drive product development of the Gamlen range of powder compaction analysers.
Gamlen Tableting and HDK Solutions are working together to drive product development of the Gamlen range of powder compaction analysers.
Gamlen Tableting has developed and patented a range of powder compaction analysers and tablet presses. Dr Michael Gamlen, Managing Director, Gamlen Tableting, said: “We are pleased to announce our ongoing relationship with HDK Solutions Ltd to help us deliver high quality software solutions and data handling systems for our powder compaction analysers. Through their in-depth understanding of the instruments we produce, HDK Solutions has now become a key contributor in our product development process, helping to drive our ongoing product development effort funded by an Innovate UK grant announced last year.
HDK Solutions Limited provides solutions to the pharmaceutical, smart energy, printing, aerospace and industrial markets, focussing on software, systems, integration and automation. Henry Kafeman, Managing Director, HDK Solutions, commented: “Over the past year, we have been able to support the development of Gamlen Tableting’s flagship products — the Gamlen D series of advanced powder compaction analysers — by developing bespoke data collection and analysis software which automatically calculates solid fraction and strain data, and produces Heckel and Kawakita plots. We are currently working on our latest concept, dynamic powder compaction analysis, which will give the user a unique insight into both the plastic and the elastic properties of their materials.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.